Since TRAIL induces apoptosis in transformed or tumor cells but not in normal cells, it is considered to be a promising cancer therapeutic agent, better than other TNF superfamily members, such as TNF and Fas ligand (14–17), which have no selectivity for normal and cancer cells. Here, FASLG is linked to cancer.